Sacrsmciito; CA 9581 7 (916'j 734-1537 Tax (9 16) Objective: To determine if emergency phq iiciatls~ IEP) UFG o!'drcq7eridr>! i-12s chiingrri sirice 1112 United Scales Food a.nd Driig Aclniinihzratio~: (FDA) warning of December 2001 coxicerning QT irikrrt al proiorgatioi:, iorsarie J e p o i~t e s , 2nd s~~cidcii de:.r",l: and ro qu:.r> EP nl,ii?iofij rcgzrding droy?eri:'.cl hefclre 2nd ~ifter t l i~ FDA. i;var.r,ing aiid regarding potcx"lal aItcrilbt:il;c drugi.
Methods: An internet-based survey was designed with y~~eslions regarding droperidol use in the emergency department (ED). Data coiiected included EP demographics, use of droperidcd before and ~ifier the FDA warniiig, use of alterilative drugs, and incidence of arrhythmias. A representative sample of EPs were contacted by e-!nail and asked to complete the survey. Results: A total of 2,000 e-mails resulted in 506 (25%) complered surveys. There was no aecond mailing. Responders" average years practicing was 12.6 2 9.2. EP responders worked in pivatelcommunity (n=278, 55%). academic/ county jn=187,37%), and HMO (i1=41,89) hospitals. The ~~~a j o r i t y (11~455, 90%) used droperidol and were aware of the FDA warning (n=460.9 i %). Droperidol was no longer avaiiable at i 22 (24%) ofthe respondents' EDs as aresult of the FDA warning. Prior to the FDA warning EPs who had used droperidcli used it as an antiemetic jn=408,90%), for conrroi of agiiaticm (n=330.73%); for treatment of headache (n=247, 54%), and for treatment of vertigo jn=106. 23%). After the FDA warning, 387 (85%) of EPs reported their use of droperidol had decreased or ceased altogether, and 68 ( 1 5 8 ) always oh~btined an elecrrocardiogra~n prior to administraiion. Of' tilose who used droperidol fix agitation: 137 (42%) felt there were no other drugs with greater efficacy. Haloperidol was the most cited alternative agent in=160, 79%) fc>c;i!o\+ ed by benzodiazepines (it=223,68% For patients in whom the potential benefit of INAPSINE treatment is felt to outweigh the risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2-3 hours after completing treatment to monitor for arrhythmias.
INAPSINE is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome.
INAPSINE should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). Other risk factors may include age over 65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile anesthetics, and PV opiates. Droperidol should be initiated at a low dose and adjusted upward, with caution, as needed to achieve the desired effect. sis,"12 nausea and emesis,13 l8 headache,lS " vertigo,?*-" and atypical pain s y n d r~m e s .~"~~ Dmperidol was commonly used by anesthesiologists for treatment of postoperahive nausea and vorniting (POW), constihtting 30% of the P O W market, with over 25 million units sold in 2000.2Vn its oral form, dsoperidol was used as an antipsychotic agent by psychiatrists, especially in Europe.' Before the FDA w a~n g , only doses greater than 25 mg were col~cidered to be at risk for QT interval proBongation and arrhythmia. Across the world, EPs. anesthesiologists, psychiahists, and pl~amacists reacted with skepticism to there new rertrictions on the use of droperidol.' 2s- 35 The purpose of this survey study war to determine if droperidol use by EPs has changed since the FDA warning.
METHODS Study Design and Population
This survey study was specifically designed for, and addressed to practicing EPs in the United States, inacademic/universiQ> countyipt~b-lic, p~ivate/communi@> md health maintenance organizatioi~ ( m O ) EDs. A questionnaire was de\ieloped in hyper text makup language (HTNIE) format tasii~g Dreamweaver (Macromedia, Sari Francisco. California), and a survey world wide web (WWW) page was set up on a dedicated server. Upon completion of the HTML survey, data was collected using ColdFusion (Macromedia, San Francisco. California) in an Access (Microsoft, Wedmsnd, Washington) database for hi-ther andy sis. This study was approved by the hsdtk~tional Review Board of the University of California, Davis Medical Centeir.
Survey Content and Administration
The first section of the survey contained questions regauding El? demogr;~p%nics, includil~g type of hospital staffed, surrounding population sewed, and years practicing emergency medicine. We obtained responses on howledge of the FDA waning and prior use of dropendo1 in the ED. Culrent availability of droperidol in the respondent's particular ED and discontinuation after the FDA walling were also queried. The next section of the s~~~v e y involved ody those physicians who use or had used droperado1 in the ED. Specific indicaeioras such as nausea and emesis, agitation. and headache were listed, and frequency of use of ciroperidol before and after the FDA war~~ing was detemined. Emergency physicians who continued to use drope6dol despite the FDA !yarning were aslced if they now obtained an eelctrocxdioga-m prior to administration. 3pinion regarding efficacy of droperidol and preferred alternative pharmaceutical agents for tl~e Bndics?'bions of agitkltlon and psychosis, as well as nausea and emesis, were queried. In addition, adverse outcomes in the f o m~ of arrhythmia or sudden death from droperidol administration were tabulated. Finally, EP opinion of the validity of the g and concern regarding loss of drope:r;ldol avi6lability altogether were also i~acluded in the questio~~raire. As a direct result of the FDA wafing, 85% (n=387) oEEPs reported theh use of dropekdol had decreased or ceased akogether ( Figure 21 , and this decline in frequency of use was significant (P < 0.1400%). The remaining 15% of EPs who still use droperidoi alwas s obtained an electrsc~~diogram psior to administration. Of those EPs who used droperldo" f w rthc treatment of agitation in fhe ED, 42% (I 37) felt &ere were no other drugs with greater effncaey. Haloperk dol was the lnosl frequently c~ted alternative agent 
Frequency of Use
Figare 2, Frequency of Droperidsl Use before and after the FDA Warning 79% (r-r=260) foliorn7ed by benzodiazepines m 68% (n=223) ( Table 2) . Or" tho% who used ctroperidol for antierz~esis, 28% ((n= 1 I&) felt there were no other & X I~S with greater efilcacy, md promethalzine was the most cited alterxlative agent by 63% in=%68)( Table  3) . TWO (0.4%) EFs repor-ted arI~yt'ranGas in patitie~~ts who received droperidol, but no cleat115 were repomd.
Opinion regarding overall utiiity of droperidol as a drug in the ED declined sig~ficantly as a result of the FDA warning (P < 0.009), tvith ZOO (44%) EPs rating droperidol as "extremely rascful'' prim to the U~~I T Iing. and just 69 (15%) giving it the s;mx rating after the warning. Tlaree huladred and four respondents (67%) aaaswered that the FDA t c arning had a direct affect on their ability to ireat patients in the ED Emergency physicians were q~~e~l e d sn their opm?on of the FDA warning, and 242 (53%) felt it was ur~justified. Twenty (4%) EQs felt the warning was completely appropriate, and two (0.4%) felt droperidol should be banned altogether. Onzly 37 (8%) EBs reported they were unconcerned with potential loss of droperidol from the market, as has occurred in Europe.
DISCUSSION
The results of this survey demonstrate the impact the FDA warning on dl-operidoi has had on prac"rcing EPs' use of the drug. Those paaicipating in the burvey now use droperidol rn~lch less frequeaztly or not at all, and many now have no access to Qoper;dol. h also outlines the skepticism many EPs harbor towad the validity and ;113pmpnaateness of the FDA wm~ing, md that alternative naedicaiions may not be perceived to be as effective as dropesidol for a variety of indications. The ackrraI practice experience of EPs does ~r l~~t~j md exbeineky ihsw cost -spay also exp1i.n the outcTy f:hat accompa.~~':cd 'its loss in Europe" Mter file co~nplete avi tl~ds-k~~h~d of tboperidol in Europe by 95s rna~au&~-l,ctui~er Janssen-Giiag, Trzme~. arnd cofieagues emphasized the d'iscsntinurdon was in response to adverse events liraited with chronic, 1argc k or;?% ~O S~S given to psvchn:' 1 r i i~i "-' IC p&t$iie~~tS, 1109 the sIq I a1 qa3-bl ;ntravealo~s -. doses give11 $0 POTPJ patient^.^"
!:his g r o u~ called for a distirsciion to be made be-+< en ' = the two indications so that low-dose i111rave-niius dropefidol could be used in the perjoperative setting. I-Hiaines et a1 also emphasized this distinction, and mentioned the consequences to the national he~alth budget in the Lhnited Kh~gdom Gor-n loss of &ope~idol and rise of the newer serotonin type 3 antagonist^.^' A similar protest was heard frorn Lehot and Ferry in France,.Q FoilovV~ing the FDA w i~~i c g , an even stronger outc~=y o c c u~~e d in the United States, In an article investigating the actual adverse outcomes listed by the FDA, Horo\vitz and associates, refenjng to droperidol as "one of the most used emergency medications now," suggested the link between droperidol and QT interval prolongation. torsade de pointes, and sudden c ;~-diac death was not at a13 clear.' They noted many of the deaths or adverse outcolnes provided by the FDA were patients who were already critically ill and/or concomitantly taking several potea~tially mhytlmoge~lic ~~~edirsations. Bailey et d similzly investigated the actual adverse cases used by the FDA to justify the wdming and reached the same conclmsion." Can and colleagues determined the cost of preventing PONV was over 40 times higher to the patient when ondansetron was used indead of droperidol. and "rat prior to ihe FDA warnirrg droperidof had a 50% ~onarhet share.:" Thic group wrote "we believe thas the recent black box warning by the FDA is totally unj~~stified," and called for the 
LIMITATIONS
The most important limitation ofthis study is that it is a survey based or? srzbjective answers and opinions of a small sarnple of EPs, z~d nnay not reflect act~eal practice. F-kar"r~ermore, those who responded may have been motivated to do so because of a stronger than a-zTerage positive or negative opinion regarding droperidoi. There were many non-responders, and several inaccurate, invalid, of-expired e-mail addresses. The loss of these potential survey participants may have affected the results of the study. In 10. Hick JE. Mahoney BD. Eappe M. Prehospital sedation order to maintain respondents' privacy, follow up surveys were not e-mailed to ~mn-i-esponders, or to those 5ublnikthg hcornpiete sweys. Respo~lsients may have felt their participation in the srervey would result in their e-mail identity being prolnulgated,
CONCLUSION
Among those EPs replying to this survey, use of droperidol decreased dramatically as a result of the FDA warning. Over half the suwey resporsdenks feel the FDA w~l~g is u~~jusdfied and are copzcerned by the pote~~tial loss or h11311er rest~jction of drope~dol in the United States. Many of the d~xegs listed by EPs as alternatives to droperidol, such as hitloperidol, cMorpromazine, rispesidone, and dsIase&on also have risk of QT intenla9 prolongation. Beca~rse of limited alternative therapies, as well as tlaeir side effect profile and expense, many EPs ,and anestl~esiologists question the FDRs action.
Training in emergency medicine is full of fascinating encounters. Over the course of medical school and residency we will amash a h~age body of inta~agible experience. Much of this we share with our i m e d iate peers, residents, and classmates, as a para of our own coping and cahloguing mecl~misms. However, much of it is also an important part of our learning process. I cannot begin to relay how much Y have learned, not from books (I will never read as much as my residency director would like me to) bent from the experience of my fellow residents. Not only have 1 leafned about the practice of medicine, but about the practice of life as a medical professional. This ES 2 1 new section for this journal, As it starads there are no official boursdaries. Wc (the colh"ective reiidentisaudent population) can fill it as we see fit. There are many o~atlets for statishcalgy s~gniii'icant rmdomized, Minded, meta-prospective studie5 about vasiable dosing of phenytoin in post-ictd rats. Hswever, these are very few place$ to share on a wider front, the more nebulous. but nor necessarily less irnportant experiential aspects of our training. (Pva, 7c>w . that sorinds abit hew-agey.') HopefuUy tkis will spark some interesting disc~rssio~~ and we can l e m aad laugh a little in the process.
Submissio~~s of any kind (interesting stories, poems, prose, f k t , fiction, and outside-the-box research proposals) nnay be sent 'so Jason Quinn jquirm@hghed~com,
